太极集团：获得司美格鲁肽注射液药物临床试验批准通知书

Core Viewpoint - Taiji Group's subsidiary has received approval for clinical trials of Semaglutide injection, indicating a significant step in diabetes treatment and weight management [1] Company Summary - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Semaglutide injection [1] - Semaglutide is a long-acting GLP-1 receptor agonist that stimulates insulin production, suppresses glucagon secretion, and reduces appetite and food intake [1] Industry Summary - Semaglutide plays a crucial role in the treatment of type 2 diabetes and assists in weight management, highlighting its importance in the pharmaceutical industry [1]